Medication Monitor



Generic Name (Trade Name—Company)
Notes
March 27, 2018

Tildrakizumab-asmn

(Ilumya—Sun Pharma)
FDA approves tildrakizumab-asmn for plaque psoriasis

Sun Pharmaceuticals announced FDA approval of tildrakizumab-asmn for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Tildrakizumab-asmn is an interleukin (IL) inhibitor that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor, leading to inhibition of the release of proinflammatory cytokines and chemokines. 

The agent is administered at a dose of 100 mg by S.C. injection every 12 weeks, after the completion of initial doses at weeks 0 and 4.

It is contraindicated in patients with a previous serious hypersensitivity reaction to tildrakizumab or to any of the excipients.